Last reviewed · How we verify

NCT05688917

Green Coffee Effect on Metabolic Syndrome

Completed NA Last updated 26 May 2023
What this trial tests

NA trial testing Green coffee been extract in Supportive Care in 160 participants. Completed in 30 September 2022.

Timeline
3 September 2020
Primary endpoint
1 September 2022
30 September 2022

Quick facts

Lead sponsorTanta University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment160
Start date3 September 2020
Primary completion1 September 2022
Estimated completion30 September 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Tanta University

Who can join

Adults 20 to 60, any sex, with Supportive Care or Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present study aimed to investigate the effect of green coffee bean extract (GCBE) on the inflammatory biomarkers in obese patients with a metabolic syndrome via analyzing some inflammatory biomarkers as resistin, TNF-α, total sialic acid, homocysteine, high sensitivity C-reactive protein (hs-CRP) and anti-inflammatory cytokine, adiponectin

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect of green coffee on miR-133a, miR-155 and inflammatory biomarkers in obese individuals.
    Khedr NF, Zahran ES, Ebeid AM, Melek ST, et al · · 2024 · cited 2× · PMID 39468643 · DOI 10.1186/s13098-024-01478-7

Verify or expand the search:

Other recruiting trials for Supportive Care

Currently open trials in the same condition.

Other Tanta University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05688917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing